Barclays initiated coverage of Amedisys with an Equal Weight rating and $93 price target. The analyst is positive on home health industry volume growth within post-acute care longer term. However, the firm sees near-term pressure on capturing volume due to labor shortages, and pressure on rates.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AMED:
- Amedisys Board Appoints Richard Ashworth as New President and Chief Executive Officer
- Amedisys, nVoq present outcomes from speech recognition study
- Amedisys to Present at Multiple Healthcare Conferences in March
- Amedisys to participate in a conference call with Truist
- Amedisys partners with BlueCross BlueShield of Tennessee
